Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2031

Annual patent cliff calendar for 2031 — US pharmaceutical patents by expiration date.

Patents
902

Quick answer

902 indexed pharmaceutical patents have expiration dates in 2031. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 8049015

    Heteroaryl antagonists of prostaglandin D2 receptors

    Panmira Pharmaceuticals, LLC · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8048902

    Antagonists of lysophosphatidic acid receptors

    AMIRA PHARMACEUTICALS, INC. · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8048418

    Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8049016

    Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes

    Xenon Pharmaceuticals Inc. · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8048415

    Compositions and methods for promoting or inhibiting angiogenesis

    Northwestern University · Granted Tue Nov 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8053412

    NELL-1 peptides

    The Regents of the University of California · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8052970

    Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8053416

    Isolation and structure of turbostatins 1-4

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8053422

    Anti-cancer oligodeoxynucleotides

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8053434

    Kinase inhibitors and their uses

    Rigel Pharmaceuticals, Inc. · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8053443

    N-substituted indenoisoquinolines and syntheses thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8053487

    Multifunctional acrylates used as cross-linkers in dental and biomedical self-etching bonding adhesives

    United States of America as represented by the Secretary of the Air Force · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8053448

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance, Inc. · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8053424

    Composition and method of treating hearing loss

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 03 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8058226

    Albumin-free factor VIII formulations

    UNIVERSITY OF CONNECTICUT · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8057807

    Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8058244

    Cyclic peptide antitumor agents

    Northwestern University · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8058248

    Foot and mouth disease virus vaccine comprising interferons

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8058300

    Polycyclic antagonists of lysophosphatidic acid receptors

    AMIRA PHARMACEUTICALS, INC. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8058280

    Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8058249

    Immunostimulatory nucleic acid molecules

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8058271

    Selective inhibitors of rock protein kinase and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8058295

    Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

    The Regents of the University of California · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8058446

    Certain substituted amides, method of making, and method of use thereof

    GILEAD CONNECTICUT, INC. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8057990

    Screening method

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8058025

    Methods for determining efficacy of chemotherapeutic agents

    Precision Therapeutics, Inc. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8058237

    Stable composition of GDF-5 and method of storage

    Advanced Technologies and Regenerative Medicine, LLC · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8057810

    Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application

    Obschestvo S Ogranichennoi Otvetstvennostyu “Sia Peptides” · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8058385

    Method for preparing conjugates using polymer maleimides

    Nektar Therapeutics · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8058257

    Compositions and methods for inhibiting expression of a gene from the JC virus

    Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8058403

    Antibodies to stromal cell-derived factor-1 polypeptides

    Five Prime Therapeutics, Inc. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8058268

    Neuroprotective agents for the prevention and treatment of neurodegenerative diseases

    Lixte Biotechnology, Inc. · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8058063

    Method of producing region-specific neurons from human neuronal stem cells

    The Board of Regents of the University of Texas System · Granted Tue Nov 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8063211

    Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8063248

    Sphingosine kinase inhibitors

    Apogee Biotechnology Corporation · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8063047

    Pyridazine compounds and methods

    Northwestern University · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8063066

    MAPK/ERK kinase inhibitors

    Takeda Pharmaceutical Company Limited · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8063195

    Mutations in a toll-like receptor motif in the NS4B of classical swine fever virus strain brescia influences virulence in swine

    The United States of America, as represented by the Secretary of Agriculture · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8062654

    Drug releasing biodegradable fiber for delivery of therapeutics

    The Board of Regents of the University of Texas System · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8063057

    Multicyclic amino acid derivatives and methods of their use

    LEXICON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8063084

    Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels

    Xenon Pharmaceuticals Inc. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8063014

    Self-assembly of peptide-amphiphile nanofibers under physiological conditions

    Northwestern University · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8062640

    High affinity human antibodies to PCSK9

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8062647

    High concentration baclofen preparations

    The Board of Regents of the University of Texas System · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8062643

    Use of neurotoxin therapy for treatment of urologic and related disorders

    The Regents of the University of Colorado · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8063089

    Inhibitors of nucleophosmin (NPM) and methods for inducing apoptosis

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8063209

    Phosphonyl ester conjugates as prodrugs

    The United States of America as represented by the Department of Health and Human Services (DHHS) · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8063250

    Crystal forms of O-desmethylvenlafaxine fumarate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2031?

902 published patents in our USPTO index have expiration dates falling in calendar year 2031.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.